Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, an antibody drug candidate targeting the cannabinoid receptor 1 (CB1) for obesity and metabolic disorders. Skye has no approved products and generates no revenue. Nimacimab is a peripherally restricted, humanized antibody that blocks CB1 in peripheral tissues — fat cells, liver, pancreas, and gut — without meaningfully crossing the blood-brain barrier. This mechanism is designed to deliver the weight loss and metabolic benefits of CB1 inhibition while avoiding the neuropsychiatric side effects that caused earlier CB1 inhibitors to be withdrawn from the market. Skye is pursuing two clinical strategies for nimacimab: as a combination therapy alongside GLP-1 agonists like semaglutide to enhance weight loss and reduce rebound, and as a monotherapy or maintenance option for patients who cannot tolerate or don't respond to GLP-1 drugs. Phase 2a data showed the nimacimab-plus-semaglutide combination achieved -13.2% weight loss vs. -10.25% for semaglutide alone, with substantially less weight rebound after stopping treatment. Skye is now planning a Phase 2b dose-ranging study, pending FDA feedback and additional capital. Skye acquired nimacimab through its 2023 acquisition of Bird Rock Bio, operates with roughly 12 employees, and relies on CROs and CMOs for clinical and manufacturing operations. The company's cash runway extends through at least Q1 2027 but does not cover Phase 2b or Phase 3 costs, meaning Skye will need to raise additional capital or secure a partnership to advance the program further.